ADC Technology

Antibody-drug conjugates (ADCs) represent a promising modality for delivering cytotoxic drugs to targeted tumor cells while avoiding off-tumor toxicities. ​

Despite successes in the past 20 years, development of effective ADCs with broad therapeutic window remains challenging due to the complexity of conjugation technologies and the instability of the linkers. ​

OBI not only developed a cysteine-based conjugation platform but also a unique glycan ADC platform (GlycOBI™), which are in a ‘Plug and Play’ format and compatible with any antibodies, linkers, and payloads in various Drug antibody ratio (DAR). Especially, GlycOBI™ is an efficient and scalable process to generate site-specific homogenous ADCs. This platform overcomes the limitations of traditional ADCs, resulting in the improvement of efficacy and stability. ​

This was achieved by utilizing OBI proprietary enzymatic technology (EndoSymeOBI™), followed by conjugating the hydrophilic linker-payload with the glycan site of antibody naturally occurring in the antibody’s Fc region. The conjugation process avoids disrupting the antibody structure, ensuring the related ADC has similar biophysical characteristics compared to native antibody. ​

Furthermore, OBI linker technology improves the conjugation efficiency of the payload, as well as reduces the aggregation propensity, and expands the half-life of the ADC products.

Platform

Technology Area

Potential Application

Platform

GlycOBI™

Technology Area:

Glycan site-specific conjugation technology

Potential Application:

Cancer treatment

OBI has developed a unique glycan ADC platform (GlycOBI™), which are in a ‘Plug and Play’ format and compatible with any antibodies, linkers, and payloads in various Drug antibody ratio (DAR). Utilizing OBI’s proprietary enzymatic technology (EndoSymeOBI™) and novel linker-payload technology, GlycOBI generates site-specific homogenous ADCs with an efficient and scalable process. The conjugation process of GlycOBI avoids disrupting the antibody structure and ensures the ADC has similar biophysical characteristics to the native antibody. Furthermore, OBI’s linker technology has improved conjugation efficiency of the payload and reduced aggregation propensity, and also expanded the half-life of the ADC products. GlycOBI has overcome the limitations of traditional ADCs and achieved better efficacy and stability in various in vivo tests.

Platform

EndoSymeOBI™

Technology Area:

Enzymatic technology​

Potential Application:

Cancer treatment

EndoSymeOBI is our pioneer enzyme technology which allows antibody glycan modification within a single step, including removing multiple types of sugar molecules and linking specially designed sugar molecules or their derivatives to the antibody. Giving the needs of drug development, EndoSymeOBI processed antibody retain its stability and binding activity without altering disulfide bonds. The EndoSymeOBI platform excels in diverse applications from sugar molecule removal to site-specific antibody-drug conjugate (ADC) production, and antibody homogenization. EndoSymeOBI directly enhances the functionality of antibodies, offering more effective solutions for developing therapeutics for cancer, immune system diseases and others.

Partner with Us

OBI operates with an excellent management team and efficient management model to create an international Taiwan brand, and to base in Taiwan and expand the horizon worldwide.